Pub Date : 2023-03-29DOI: 10.30683/1929-2279.2023.12.4
Nada A. Al-Hasawi, L. Novotný
Mercury (Hg) is a toxic heavy metal to which we are exposed in everyday life. Exposure to environmental Hg may lead to toxicity in the human body associated with major health issues. Quercetin (QE) on the other hand, is a natural flavonoid widely distributed in higher plants and is part of the human diet. Several studies demonstrated the therapeutic and protective effects of QE against multiple diseases and health problems. The aim of this study is to investigate the effect of QE and Hg on the proliferation of human astrocytoma 1321N1 cell line. This study is a continuation of our previous work in which we investigated cadmium (Cd) instead of Hg. The 1321N1 cells were either treated with Hg alone, or pre- or co-treated with QE. Cell viabilities were determined by MTT assay. Results indicated that simultaneous treatment of the cells with 200 µM and 16 µM Hg for 48 hrs significantly reduced cell viability to 11.7 ± 3.1 % compared to the DMSO vehicle-treated cells. Other experiments of QE pre-treatment followed by exposure to Hg alone or with QE indicated a significant ability to reduce proliferation compared to treatment with Hg alone. In conclusion, our study suggested a synergistic anti-proliferative interaction of Hg and QE in malignantly transformed cells. However, this effect is higher when combining Cd and QE as indicated in our previous work. These data may be beneficial in exploiting the biological effect of QE for treating the malignantly transformed cells.
{"title":"Quercetin and Mercury In Vitro Anti-Proliferative Effect in Human Astrocytoma Cells","authors":"Nada A. Al-Hasawi, L. Novotný","doi":"10.30683/1929-2279.2023.12.4","DOIUrl":"https://doi.org/10.30683/1929-2279.2023.12.4","url":null,"abstract":"Mercury (Hg) is a toxic heavy metal to which we are exposed in everyday life. Exposure to environmental Hg may lead to toxicity in the human body associated with major health issues. Quercetin (QE) on the other hand, is a natural flavonoid widely distributed in higher plants and is part of the human diet. Several studies demonstrated the therapeutic and protective effects of QE against multiple diseases and health problems. The aim of this study is to investigate the effect of QE and Hg on the proliferation of human astrocytoma 1321N1 cell line. This study is a continuation of our previous work in which we investigated cadmium (Cd) instead of Hg. The 1321N1 cells were either treated with Hg alone, or pre- or co-treated with QE. Cell viabilities were determined by MTT assay. Results indicated that simultaneous treatment of the cells with 200 µM and 16 µM Hg for 48 hrs significantly reduced cell viability to 11.7 ± 3.1 % compared to the DMSO vehicle-treated cells. Other experiments of QE pre-treatment followed by exposure to Hg alone or with QE indicated a significant ability to reduce proliferation compared to treatment with Hg alone. In conclusion, our study suggested a synergistic anti-proliferative interaction of Hg and QE in malignantly transformed cells. However, this effect is higher when combining Cd and QE as indicated in our previous work. These data may be beneficial in exploiting the biological effect of QE for treating the malignantly transformed cells.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44248908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-21DOI: 10.30683/1929-2279.2023.12.3
A. Govindan, J. Alapatt
Background – Meningiomas are common tumors of the Central Nervous System. Recurrence in meningiomas has been proven to be associated with factors like extent of resection and grade of tumor. Decrease in progesterone receptor expression has been linked to increased rate of recurrence. We undertook this study to know about progesterone and estrogen receptor expression in meningiomas and its association with different clinicopathological variables as data is lacking in the Indian population. Materials and Methods – Meningiomas operated in a tertiary referral centre of North Kerala, India in 2 years were taken into the study. The tumors were graded and immunohistochemistry was performed using antibodies to Estrogen and progesterone receptors (ER&PR) and Ki-67. The expression of PR and ER was correlated with clinicopathologic variables. The patients were followed up for 2 years. Results – Grade I and grade II tumors constituted 85.3% and 14.7% respectively of the total number of meningioma cases. There were no grade III tumors in the series. The average PR positivity in grade I tumors (60.77%) was higher than in grade II tumors (46.88%). There was no gender related difference in PR staining. ER positivity was found only in a few cases. Conclusion – PR deterioration was associated with increased cell turnover. Meningiomas occurring in this study population are similar in clinicopathological parameters to those tumors occurring in other parts of the country but different in some aspects like grade from tumors occurring in other parts of the world. Strict follow up of a larger cohort of patients for a longer time period will be required to draw conclusions about prognosis in this population.
{"title":"Progesterone and Estrogen Receptors in Meningiomas – A Clinicopathological Analysis","authors":"A. Govindan, J. Alapatt","doi":"10.30683/1929-2279.2023.12.3","DOIUrl":"https://doi.org/10.30683/1929-2279.2023.12.3","url":null,"abstract":"Background – Meningiomas are common tumors of the Central Nervous System. Recurrence in meningiomas has been proven to be associated with factors like extent of resection and grade of tumor. Decrease in progesterone receptor expression has been linked to increased rate of recurrence. We undertook this study to know about progesterone and estrogen receptor expression in meningiomas and its association with different clinicopathological variables as data is lacking in the Indian population. \u0000Materials and Methods – Meningiomas operated in a tertiary referral centre of North Kerala, India in 2 years were taken into the study. The tumors were graded and immunohistochemistry was performed using antibodies to Estrogen and progesterone receptors (ER&PR) and Ki-67. The expression of PR and ER was correlated with clinicopathologic variables. The patients were followed up for 2 years. \u0000Results – Grade I and grade II tumors constituted 85.3% and 14.7% respectively of the total number of meningioma cases. There were no grade III tumors in the series. The average PR positivity in grade I tumors (60.77%) was higher than in grade II tumors (46.88%). There was no gender related difference in PR staining. ER positivity was found only in a few cases. \u0000Conclusion – PR deterioration was associated with increased cell turnover. Meningiomas occurring in this study population are similar in clinicopathological parameters to those tumors occurring in other parts of the country but different in some aspects like grade from tumors occurring in other parts of the world. Strict follow up of a larger cohort of patients for a longer time period will be required to draw conclusions about prognosis in this population.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45326730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-14DOI: 10.30683/1929-2279.2023.12.2
K. Mojica, J. Massari, José R. Rodríguez, J. Olalde, Miguel J. Berdiel, Michael J. González
It is a common practice to envision cancer exclusively as a genetic disease, however, in our perspective, changes in gene expression leading to malignancy are secondary to biochemical disturbances and at its core we consider cancer as a metabolic energetic disease. In this regard, incongruence with the concept of the bioenergetic theory of carcinogenesis, we propose structured water (EZ water), as an element that facilitates the correction of the fundamental energy disruption and the reestablishment of health. The prime approach for this therapy would be to infuse kosmotropic osmolytes by the intravenous route to improve the physiological conditions and promote the reduction of cancer growth with no side effects. By doing so, we could expect that the cells will regain their communication ability with a functioning Ras and p53 proteins and other metabolic and transcription factors. The end goal is to support the cell in overcoming its low-energy anaerobic glycolytic metabolism that favors uncontrolled growth and regain the full energetic potential of oxidative phosphorylation that supports controlled cell division and differentiation. To achieve this goal, we propose the use of metabolic correction to improve the membrane function of the mitochondria. The use of precursors, enzymatic cofactors, and a variety of biological response modifiers which includes structured water and its kosmotropic properties in enzyme dynamics are part of the metabolic correction concept.
{"title":"Structured Water and Cancer: Orthomolecular Hydration Therapy","authors":"K. Mojica, J. Massari, José R. Rodríguez, J. Olalde, Miguel J. Berdiel, Michael J. González","doi":"10.30683/1929-2279.2023.12.2","DOIUrl":"https://doi.org/10.30683/1929-2279.2023.12.2","url":null,"abstract":"It is a common practice to envision cancer exclusively as a genetic disease, however, in our perspective, changes in gene expression leading to malignancy are secondary to biochemical disturbances and at its core we consider cancer as a metabolic energetic disease. In this regard, incongruence with the concept of the bioenergetic theory of carcinogenesis, we propose structured water (EZ water), as an element that facilitates the correction of the fundamental energy disruption and the reestablishment of health. The prime approach for this therapy would be to infuse kosmotropic osmolytes by the intravenous route to improve the physiological conditions and promote the reduction of cancer growth with no side effects. By doing so, we could expect that the cells will regain their communication ability with a functioning Ras and p53 proteins and other metabolic and transcription factors. The end goal is to support the cell in overcoming its low-energy anaerobic glycolytic metabolism that favors uncontrolled growth and regain the full energetic potential of oxidative phosphorylation that supports controlled cell division and differentiation. To achieve this goal, we propose the use of metabolic correction to improve the membrane function of the mitochondria. The use of precursors, enzymatic cofactors, and a variety of biological response modifiers which includes structured water and its kosmotropic properties in enzyme dynamics are part of the metabolic correction concept.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46777902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-06DOI: 10.30683/1929-2279.2023.12.1
K. Ina, Y. Kato, K. Nanya, S. Hibi, Y. Shirokawa, Tomoko Toda, S. Kayukawa
Background: Remarkable progress in cancer genomic medicine (CGM) has been made with the advent of next-generation sequencing and advanced computational data analysis approaches. In Japan gene panel testing has been covered by the National Health Insurance System since June 2019. Although Nagoya Memorial Hospital has been designated as a regional medical support hospital, their medical staff are unfamiliar with CGM and generally experience difficulty in explaining the genetic testing to cancer patients. Methods: A multi-disciplinary CGM team was created in July 2019 to adapt to the clinical application of gene panel testing. Hospital functions were then maintained focusing on the following three aspects: a pathology system for handling genetic information, human resource development related to CGM, and a patient support system, including genetic counseling. Results: Third party ISO15189 (International Organization for Standardization) certification was acquired for the Department of Pathology to establish a quality-assured laboratory. Here, we report on 21 cancer patients who consulted and received information from the CGM outpatient department of our hospital. Among them 14 patients were introduced into a group of certified hospitals by the Japanese Ministry of Health, Labour, and Welfare and 10 patients underwent gene panel tests. Conclusions: As a regional medical support hospital dealing with many cancer patients, we will further improve hospital functions to match the progress in CGM.
{"title":"Adaptation to the Progress in Cancer Genomic Medicine by a Japanese Community Hospital","authors":"K. Ina, Y. Kato, K. Nanya, S. Hibi, Y. Shirokawa, Tomoko Toda, S. Kayukawa","doi":"10.30683/1929-2279.2023.12.1","DOIUrl":"https://doi.org/10.30683/1929-2279.2023.12.1","url":null,"abstract":"Background: Remarkable progress in cancer genomic medicine (CGM) has been made with the advent of next-generation sequencing and advanced computational data analysis approaches. In Japan gene panel testing has been covered by the National Health Insurance System since June 2019. Although Nagoya Memorial Hospital has been designated as a regional medical support hospital, their medical staff are unfamiliar with CGM and generally experience difficulty in explaining the genetic testing to cancer patients. \u0000Methods: A multi-disciplinary CGM team was created in July 2019 to adapt to the clinical application of gene panel testing. Hospital functions were then maintained focusing on the following three aspects: a pathology system for handling genetic information, human resource development related to CGM, and a patient support system, including genetic counseling. \u0000Results: Third party ISO15189 (International Organization for Standardization) certification was acquired for the Department of Pathology to establish a quality-assured laboratory. Here, we report on 21 cancer patients who consulted and received information from the CGM outpatient department of our hospital. Among them 14 patients were introduced into a group of certified hospitals by the Japanese Ministry of Health, Labour, and Welfare and 10 patients underwent gene panel tests. \u0000Conclusions: As a regional medical support hospital dealing with many cancer patients, we will further improve hospital functions to match the progress in CGM.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46525583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-11-02DOI: 10.30683/1929-2279.2022.11.11
S. Hibi, K. Ina, S. Yuasa, Nobuto Ito, Y. Shirokawa, K. Nanya, Y. Kato, T. Yoshida, S. Kayukawa
The reactivation of the hepatitis B virus (HBV) following systemic chemotherapy reportedly caused acute liver dysfunction as a fatal complication. HBV reactivation sometimes occurs even after the cessation of chemotherapy, especially in the patients with hematological malignancies. A retrospective survey of patients with hepatitis B surface (HBs) antigen-negative cancer with HBs and/or HBc antibodies was conducted by a multidisciplinary chemotherapy team to determine the examination rate of the HBV DNA test after the completion of chemotherapy. Among 83 patients with a resolved HBV infection, who were followed up for more than 3 months, only 17 patients underwent HBV DNA monitoring every 1-3 months (17/83; 20.5%). Since September, 2022, the chemotherapy team has informed the attending physician regarding the continuous HBV DNA monitoring in patients with cancer with a resolved HBV infection until 12 months after the cessation of chemotherapy.
{"title":"Management of Hepatitis B Virus Reactivation after the Completion of Cancer Chemotherapy using a Plan-do-Check-Act Cycle","authors":"S. Hibi, K. Ina, S. Yuasa, Nobuto Ito, Y. Shirokawa, K. Nanya, Y. Kato, T. Yoshida, S. Kayukawa","doi":"10.30683/1929-2279.2022.11.11","DOIUrl":"https://doi.org/10.30683/1929-2279.2022.11.11","url":null,"abstract":"The reactivation of the hepatitis B virus (HBV) following systemic chemotherapy reportedly caused acute liver dysfunction as a fatal complication. HBV reactivation sometimes occurs even after the cessation of chemotherapy, especially in the patients with hematological malignancies. A retrospective survey of patients with hepatitis B surface (HBs) antigen-negative cancer with HBs and/or HBc antibodies was conducted by a multidisciplinary chemotherapy team to determine the examination rate of the HBV DNA test after the completion of chemotherapy. Among 83 patients with a resolved HBV infection, who were followed up for more than 3 months, only 17 patients underwent HBV DNA monitoring every 1-3 months (17/83; 20.5%). Since September, 2022, the chemotherapy team has informed the attending physician regarding the continuous HBV DNA monitoring in patients with cancer with a resolved HBV infection until 12 months after the cessation of chemotherapy.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43610873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-27DOI: 10.30683/1929-2279.2022.11.09
S. Nandi, M. C. Bagchi
Cancer or malignancy can be defined as abnormal growth and cell division. Malignancies spread, through metastasis invasion, or implantation into distant sites by which cancer cells can move through the bloodstream or lymphatic system to distant locations. The body cells follow mitotic cell division process. Normal cell division occurs through the normal signal transduction through proto-oncogenes responsible for the cell proliferation and differentiation. Mutation of these proto-oncogene leads to oncogene which can modify the gene expression and function through abnormal signal transduction, making uncontrolled growth of cells. The mitotic cell cycle is regulated by the signal transduction through the cyclin dependent kinases (CDKs), Ras-ERK and PI3K-Akt.Abnormal signaling occurs through the mutation of these genes leading to the cancer. The present review shortly reported the role of these proteins in abnormal signal transduction and cancer.
{"title":"Exploring CDKs, Ras-ERK, and PI3K-Aktin Abnormal Signaling and Cancer","authors":"S. Nandi, M. C. Bagchi","doi":"10.30683/1929-2279.2022.11.09","DOIUrl":"https://doi.org/10.30683/1929-2279.2022.11.09","url":null,"abstract":"Cancer or malignancy can be defined as abnormal growth and cell division. Malignancies spread, through metastasis invasion, or implantation into distant sites by which cancer cells can move through the bloodstream or lymphatic system to distant locations. The body cells follow mitotic cell division process. Normal cell division occurs through the normal signal transduction through proto-oncogenes responsible for the cell proliferation and differentiation. Mutation of these proto-oncogene leads to oncogene which can modify the gene expression and function through abnormal signal transduction, making uncontrolled growth of cells. The mitotic cell cycle is regulated by the signal transduction through the cyclin dependent kinases (CDKs), Ras-ERK and PI3K-Akt.Abnormal signaling occurs through the mutation of these genes leading to the cancer. The present review shortly reported the role of these proteins in abnormal signal transduction and cancer.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49333400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-27DOI: 10.30683/1929-2279.2022.11.10
Joseph V. Pergolizzi Jr., J. LeQuang
Almost 40% of cancer patients have neuropathic pain or mixed pain with a neuropathic component, which can be intense, debilitating, and challenging to treat. New studies on sigma receptors show these enigmatic ligand-binding protein chaperones may be helpful drug targets for new pharmacologic options to reduce many types of neuropathies, including chemotherapy-induced peripheral neuropathy (CIPN) and other cancer-related neuropathic pain syndromes. Our objective was to review the literature, including preclinical findings, in support of sigma-1 receptor (S1R) antagonists in reducing neuropathic pain and sigma-2 receptor (S2R) agonists for neuroprotection. The mechanisms behind these effects are not yet fully elucidated. The role of S1R antagonists in treating CIPN appears promising. In some cases, combination therapy of an opioid—which is a true analgesic—with a S1R antagonist, which is an anti-hyperalgesic and anti-allodynic agent, has been proposed. Of interest, but not well studied is whether or not S1R antagonists might be effective in treating CIPN in patients with pre-existing peripheral diabetic neuropathy. While neuropathic syndromes may occur with hematologic cancers, the role of S1R agonists may be effective. Sigma receptors are being actively studied now for a variety of conditions ranging from Alzheimer’s disease to Parkinson’s disease as well as neuropathic pain.
{"title":"Sigma Antagonists for Treatment of Neuropathic Pain Syndromes in Cancer Patients: A Narrative Review","authors":"Joseph V. Pergolizzi Jr., J. LeQuang","doi":"10.30683/1929-2279.2022.11.10","DOIUrl":"https://doi.org/10.30683/1929-2279.2022.11.10","url":null,"abstract":"Almost 40% of cancer patients have neuropathic pain or mixed pain with a neuropathic component, which can be intense, debilitating, and challenging to treat. New studies on sigma receptors show these enigmatic ligand-binding protein chaperones may be helpful drug targets for new pharmacologic options to reduce many types of neuropathies, including chemotherapy-induced peripheral neuropathy (CIPN) and other cancer-related neuropathic pain syndromes. Our objective was to review the literature, including preclinical findings, in support of sigma-1 receptor (S1R) antagonists in reducing neuropathic pain and sigma-2 receptor (S2R) agonists for neuroprotection. The mechanisms behind these effects are not yet fully elucidated. The role of S1R antagonists in treating CIPN appears promising. In some cases, combination therapy of an opioid—which is a true analgesic—with a S1R antagonist, which is an anti-hyperalgesic and anti-allodynic agent, has been proposed. Of interest, but not well studied is whether or not S1R antagonists might be effective in treating CIPN in patients with pre-existing peripheral diabetic neuropathy. While neuropathic syndromes may occur with hematologic cancers, the role of S1R agonists may be effective. Sigma receptors are being actively studied now for a variety of conditions ranging from Alzheimer’s disease to Parkinson’s disease as well as neuropathic pain.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47529000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-25DOI: 10.30683/1929-2279.2022.11.08
Ya-Ping He, Li Wang, Yingfen Zhang
Objective: To investigate the effect of risk-graded care based on Caprini risk assessment model on postoperative deep vein thrombosis and quality of life in elderly patients with malignant tumors. Methods: Sixty-eight elderly patients with malignant tumors treated by surgery admitted to the Department of Geriatrics of the First Affiliated Hospital of Sun Yat-sen University from April 2021 to September 2021 were selected to be included in the control group and given routine nursing interventions in the geriatrics department, using the Autar deep vein thrombosis risk scale and cluster nursing interventions; Seventy cases of elderly patients with malignant tumors treated by surgery admitted to our geriatric department from October 2021 to 2022 were included in the observation group, and the risk-grading nursing intervention based on the Caprini risk assessment model was used in the observation group on the basis of conventional nursing interventions. The number of cases of deep vein thrombosis, D-II cluster values, average hospitalization days, nursing satisfaction, and quality of life levels were compared between the two groups. Results: The number of VTE cases and the incidence of VTE in the observation group was 0.43%(3/70) lower than that in the control group (0.89%(6/68)); the average hospital stay in the observation group (13.50+7.45) was lower than that in the control group (15.16+10.60) and the D-II aggregation value in the observation group (2.90+4.32) was lower than that in the control group (4.02+3.91); with statistically significant differences (P<0.05); the satisfaction scores of communication, safety, guidance, nursing, and nursing techniques in the observation group were (41.70+4.21), (48.53+5.12), (38.47+1.90), (56.77+3.33), (47.80+1.68) points, higher than those in the control group (30.11+8.57), (41.69+7.95), (31.75+6.95), (46.87+7.31), (36.0+9.0) points, with statistically significant differences (t-values of -10.634 to -2.404, all P<0.05); the post-intervention scores of general health, physical function, physical function, somatic pain, somatic energy, social function, emotional function, mental health, and spiritual change dimensions of quality of life in the observation group were (67.00+14.95), (65.71+25.24), (63.21+21.59), (83.63+10.65), (74.43+13.45), (70.71+20.95), (67.62+26.60), (62.60+15.12) and (76.79+20.11) and scores were higher than the control group's post-intervention scores of (57.50+19.65), (40.44+27.33), (43.01+25.86), (54.57+15.42), (42.65+20.08), (56.25+26.67), (41.18+28.87), (52.35+18.86), (66.91+23.83) scores than the control group after intervention, with statistically significant differences (t-values of -26.878 to 0.989. all P<0.05). Conclusions: Risk-graded nursing intervention based on the Caprini risk assessment model can effectively reduce the incidence of postoperative VTE in elderly patients with malignancy, improve nursing satisfaction, and enhance the quality of life of patients.
{"title":"Effect of Risk-Graded Care Based on Caprini Risk Assessment Model on Postoperative Venous Thrombosis and Health-Related Quality of Life in Elderly Patients with Malignancy","authors":"Ya-Ping He, Li Wang, Yingfen Zhang","doi":"10.30683/1929-2279.2022.11.08","DOIUrl":"https://doi.org/10.30683/1929-2279.2022.11.08","url":null,"abstract":"Objective: To investigate the effect of risk-graded care based on Caprini risk assessment model on postoperative deep vein thrombosis and quality of life in elderly patients with malignant tumors. \u0000Methods: Sixty-eight elderly patients with malignant tumors treated by surgery admitted to the Department of Geriatrics of the First Affiliated Hospital of Sun Yat-sen University from April 2021 to September 2021 were selected to be included in the control group and given routine nursing interventions in the geriatrics department, using the Autar deep vein thrombosis risk scale and cluster nursing interventions; Seventy cases of elderly patients with malignant tumors treated by surgery admitted to our geriatric department from October 2021 to 2022 were included in the observation group, and the risk-grading nursing intervention based on the Caprini risk assessment model was used in the observation group on the basis of conventional nursing interventions. The number of cases of deep vein thrombosis, D-II cluster values, average hospitalization days, nursing satisfaction, and quality of life levels were compared between the two groups. \u0000Results: The number of VTE cases and the incidence of VTE in the observation group was 0.43%(3/70) lower than that in the control group (0.89%(6/68)); the average hospital stay in the observation group (13.50+7.45) was lower than that in the control group (15.16+10.60) and the D-II aggregation value in the observation group (2.90+4.32) was lower than that in the control group (4.02+3.91); with statistically significant differences (P<0.05); the satisfaction scores of communication, safety, guidance, nursing, and nursing techniques in the observation group were (41.70+4.21), (48.53+5.12), (38.47+1.90), (56.77+3.33), (47.80+1.68) points, higher than those in the control group (30.11+8.57), (41.69+7.95), (31.75+6.95), (46.87+7.31), (36.0+9.0) points, with statistically significant differences (t-values of -10.634 to -2.404, all P<0.05); the post-intervention scores of general health, physical function, physical function, somatic pain, somatic energy, social function, emotional function, mental health, and spiritual change dimensions of quality of life in the observation group were (67.00+14.95), (65.71+25.24), (63.21+21.59), (83.63+10.65), (74.43+13.45), (70.71+20.95), (67.62+26.60), (62.60+15.12) and (76.79+20.11) and scores were higher than the control group's post-intervention scores of (57.50+19.65), (40.44+27.33), (43.01+25.86), (54.57+15.42), (42.65+20.08), (56.25+26.67), (41.18+28.87), (52.35+18.86), (66.91+23.83) scores than the control group after intervention, with statistically significant differences (t-values of -26.878 to 0.989. all P<0.05). \u0000Conclusions: Risk-graded nursing intervention based on the Caprini risk assessment model can effectively reduce the incidence of postoperative VTE in elderly patients with malignancy, improve nursing satisfaction, and enhance the quality of life of patients.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48891542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-14DOI: 10.30683/1929-2279.2022.11.07
P. Mehdipour
Introduction: Cell cycle shapes the initiation, progression and therapeutic approaches of neoplasms. An uncontrolled cell proliferation and growth are the key characteristics of either malignant or benign tumors. The programmed check points control the transition of phases through the related barriers. Therefore, balancing the carcinogenic processes may inhibit progression and facilitate a targeted-base therapy. Methods: The present study is performed in interphase. Detection of the Mosaic Phases (MPs) by Fluorescence In Situ Hybridization was confirmed by assaying the protein expression (PE) including immunofluorescence and flow cytometry. Results: The novel hypothesis reflects the presence of dual and/or multi-phases, as minor clones in single cells of breast cancer (BC) patients. This finding led to initiate a model with applicable ratio values and different MPs including G1/S, S/G2 and G1/S/G2, accompanied by normal phases (G1, S, G2). The remarkable harmonic behaviors between signal copy numbers and the corresponding PE, dual- and triple- co-expression between different cyclins combination including E/B1 and D1/E/B1 and the other involved proteins were observed. The ratio of gain to normal signals appeared to be a good prognosis for chromosome 1, but better survival was significantly obtained for this ratio in chromosome 3 Conclusion: The predisposing-diagnostic-predictive-prognostic-preventive panels may lead to innovate the CDKs inhibitor-based therapy by considering the MPs Model; and may also be considered for clinical classification, in BC and other cancers.
{"title":"Evolutionary Hypothesis in Cell Cycle of Breast Cancer Patients: Mosaic Phases in Single Cancer Cells","authors":"P. Mehdipour","doi":"10.30683/1929-2279.2022.11.07","DOIUrl":"https://doi.org/10.30683/1929-2279.2022.11.07","url":null,"abstract":"Introduction: Cell cycle shapes the initiation, progression and therapeutic approaches of neoplasms. An uncontrolled cell proliferation and growth are the key characteristics of either malignant or benign tumors. The programmed check points control the transition of phases through the related barriers. Therefore, balancing the carcinogenic processes may inhibit progression and facilitate a targeted-base therapy. \u0000Methods: The present study is performed in interphase. Detection of the Mosaic Phases (MPs) by Fluorescence In Situ Hybridization was confirmed by assaying the protein expression (PE) including immunofluorescence and flow cytometry. \u0000Results: The novel hypothesis reflects the presence of dual and/or multi-phases, as minor clones in single cells of breast cancer (BC) patients. This finding led to initiate a model with applicable ratio values and different MPs including G1/S, S/G2 and G1/S/G2, accompanied by normal phases (G1, S, G2). The remarkable harmonic behaviors between signal copy numbers and the corresponding PE, dual- and triple- co-expression between different cyclins combination including E/B1 and D1/E/B1 and the other involved proteins were observed. The ratio of gain to normal signals appeared to be a good prognosis for chromosome 1, but better survival was significantly obtained for this ratio in chromosome 3 \u0000Conclusion: The predisposing-diagnostic-predictive-prognostic-preventive panels may lead to innovate the CDKs inhibitor-based therapy by considering the MPs Model; and may also be considered for clinical classification, in BC and other cancers.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42343579","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-10-10DOI: 10.30683/1929-2279.2022.11.05
K. Akinwumi, S. T. Oloyede, O. O. Eleyowo, A. Jubril
Co-exposure to chromate (VI) compound and oral contraceptives is common in our environment especially among women working in chromate-related industries. Exposure to either chromate (VI) or oral contraceptives is linked with the etiology of several diseases including cancers and renal injury. However, there is paucity of information on the toxic effect of combined co-exposure to both compounds. The present study examines the toxicity of combined exposure to potassium dichromate (PDC) and an oral contraceptive, levonorgestrel in the kidney of female rats. Control animals were fed distilled water, while experimental rats were injected 12 mg/kg body weight of PDC once a week for six weeks and oral daily exposure to 15µg/kg body weight of levonorgestrel either alone or in combination. Absolute and relative kidney weight, renal function, oxidative stress and pathological lesion were assessed in plasma and kidney of control and experimental rats. The PDC and levonorgestrel significantly (p<0.05) increased plasma urea creatinine and malondialdehyde levels in treated-rats, while renal superoxide dismutase and glutathione-S-transferase activities were reduced by both compounds. Moreover, histopathological lesions including necrotizing nephritis was observed in the kidney of PDC-treated rats, while tubular epithelial degeneration and necrosis was observed in levonorgestrel-treated rats. Combined exposure to both compounds aggravated the increase in urea, creatinine and renal damage. Additionally, the antioxidant enzymes were further repressed in the co-treatment group. The study suggests that combined exposure to potassium dichromate and levonorgestrel worsened nephrotoxicity in rats by increasing oxidative stress.
{"title":"Toxicological Outcome of Combined Exposure to Potassium Dichromate and Levonorgestrel in the Kidney of Female Rats","authors":"K. Akinwumi, S. T. Oloyede, O. O. Eleyowo, A. Jubril","doi":"10.30683/1929-2279.2022.11.05","DOIUrl":"https://doi.org/10.30683/1929-2279.2022.11.05","url":null,"abstract":"Co-exposure to chromate (VI) compound and oral contraceptives is common in our environment especially among women working in chromate-related industries. Exposure to either chromate (VI) or oral contraceptives is linked with the etiology of several diseases including cancers and renal injury. However, there is paucity of information on the toxic effect of combined co-exposure to both compounds. The present study examines the toxicity of combined exposure to potassium dichromate (PDC) and an oral contraceptive, levonorgestrel in the kidney of female rats. Control animals were fed distilled water, while experimental rats were injected 12 mg/kg body weight of PDC once a week for six weeks and oral daily exposure to 15µg/kg body weight of levonorgestrel either alone or in combination. Absolute and relative kidney weight, renal function, oxidative stress and pathological lesion were assessed in plasma and kidney of control and experimental rats. The PDC and levonorgestrel significantly (p<0.05) increased plasma urea creatinine and malondialdehyde levels in treated-rats, while renal superoxide dismutase and glutathione-S-transferase activities were reduced by both compounds. Moreover, histopathological lesions including necrotizing nephritis was observed in the kidney of PDC-treated rats, while tubular epithelial degeneration and necrosis was observed in levonorgestrel-treated rats. Combined exposure to both compounds aggravated the increase in urea, creatinine and renal damage. Additionally, the antioxidant enzymes were further repressed in the co-treatment group. The study suggests that combined exposure to potassium dichromate and levonorgestrel worsened nephrotoxicity in rats by increasing oxidative stress.","PeriodicalId":89799,"journal":{"name":"Journal of cancer research updates","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42200747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：